PharmaShots | Incisive News in 3 Shots

Subscribe Now

Aldeyra Therapeutics

Aldeyra Therapeutics Report the Results for ADX-629 in P-II Trial for the Treatment of Atopic Dermatitis

Aldeyra Therapeutics Report the Results for ADX-629 in P-II Trial for the Treatment of Atopic Dermatitis

December 20, 2023

Aldeyra Therapeutics Entered into an Agreement with AbbVie for Reproxalap to Treat Dry Eye Disease

Aldeyra Therapeutics Entered into an Agreement with AbbVie for Reproxalap to Treat Dry Eye Disease

November 2, 2023

Aldeyra Therapeutics Reports First Patient Enrolment in the P-II Trial Evaluating ADX-629 in Atopic Dermatitis

Aldeyra Therapeutics Reports First Patient Enrolment in the P-II Trial Evaluating ADX-629 in Atopic Dermatitis

April 7, 2023

PharmaShots' Key Highlights of First Quarter 2023

PharmaShots' Key Highlights of First Quarter 2023

April 3, 2023

PharmaShots Weekly Snapshots (February 27 – March 03, 2023)

PharmaShots Weekly Snapshots (February 27 – March 03, 2023)

March 3, 2023

Aldeyra Therapeutics Reports the US FDA Acceptance of NDA for Priority Review of ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma

Aldeyra Therapeutics Reports the US FDA Acceptance of NDA for Priority Review of ADX-2191 for the Treatment of Primary Vitreoretin...

March 3, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us